Neuroprotective Strategies for Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Nonarteritic anterior ischemic optic neuropathy (NAION) is the second most common form of optic neuropathy. Most patients show no improvement over time. Until now, there is still no definitive therapy for NAION. The available literatures on the possible treatment of NAION are quite diverse and controversial. Neuroprotection strategies have been suggested as one of the potential treatments for NAION. This review aims to critically evaluate the literature on neuroprotective strategy for NAION. Methods: This report was written in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta- Analysis) guidelines. We performed a systematic literature search in Pubmed, Science Direct, Proquest, and Cochrane databases. Only neuroprotective agents that directly work in protecting neurons were included. The outcome of interest in this review is retinal ganglion cell density and apoptosis for animal studies and retinal nerve fiber layer thickness for human studies. Results: The systematic search identified 591 studies of which 24 met the eligibility criteria, including 21 animal studies and three human studies. Only a few of the studies evaluated the same treatments, showing how diverse neuroprotector treatments are currently being evaluated as NAION treatment. From 21 animal studies, 14 studies showed significantly higher retinal ganglion cell density (1.49- to 2.81-fold) with neuroprotective treatment compared to control group. Two of three human studies in this review had also found a beneficial effect of preserving retinal nerve fiber layer thickness in NAION patients. Conclusions: This review suggests the potential of neuroprotection as a viable option in the quest for an effective treatment strategy for NAION. Further studies, particularly clinical studies, are necessary to establish its efficacy in NAION patients.
Abstract
Purpose: Nonarteritic anterior ischemic optic neuropathy (NAION) is the second most common form of optic neuropathy. Most patients show no improvement over time. Until now, there is still no definitive therapy for NAION. The available literatures on the possible treatment of NAION are quite diverse and controversial. Neuroprotection strategies have been suggested as one of the potential treatments for NAION. This review aims to critically evaluate the literature on neuroprotective strategy for NAION. Methods: This report was written in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta- Analysis) guidelines. We performed a systematic literature search in Pubmed, Science Direct, Proquest, and Cochrane databases. Only neuroprotective agents that directly work in protecting neurons were included. The outcome of interest in this review is retinal ganglion cell density and apoptosis for animal studies and retinal nerve fiber layer thickness for human studies. Results: The systematic search identified 591 studies of which 24 met the eligibility criteria, including 21 animal studies and three human studies. Only a few of the studies evaluated the same treatments, showing how diverse neuroprotector treatments are currently being evaluated as NAION treatment. From 21 animal studies, 14 studies showed significantly higher retinal ganglion cell density (1.49- to 2.81-fold) with neuroprotective treatment compared to control group. Two of three human studies in this review had also found a beneficial effect of preserving retinal nerve fiber layer thickness in NAION patients. Conclusions: This review suggests the potential of neuroprotection as a viable option in the quest for an effective treatment strategy for NAION. Further studies, particularly clinical studies, are necessary to establish its efficacy in NAION patients.
참고문헌 (48)
- Miller NR, "Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy", Eye(Lond), 29, pp.65~79 (2015)
- Arnold AC, "Fluorescein angiography in acute nonarteritic anterior ischemic optic neuropathy", Am J Ophthalmol, 117, pp.222~230 (1994)
- Hattenhauer MG, "Incidence of nonarteritic anterior ischemic optic neuropathy", Am J Ophthalmol, 123, pp.103~107 (1997)
- Lee JY, "Prevalence and incidence of non-arteritic anterior ischaemic optic neuropathy in South Korea : a nationwide population-based study", Br J Ophthalmol, 102, pp.936~941 (2018)
- Xu L, "Incidence of nonarteritic anterior ischemic optic neuropathy in adult Chinese : the Beijing Eye Study", Eur J Ophthalmol, 17, pp.459~460 (2007)
- Keren S, "Visual outcome following bilateral non-arteritic anterior ischemic optic neuropathy : a systematic review and meta-analysis", BMC Ophthalmol, 17, pp.155~ (2017)
- Huang HM, "Natural history and visual outcome of nonarteritic anterior ischemic optic neuropathy in Southern Taiwan : a pilot study", Int Ophthalmol, 40, pp.2667~2676 (2020)
- Dickersin K, "Surgery for nonarteritic anterior ischemic optic neuropathy", Cochrane Database Syst Rev, 2015, pp.CD001538~ (2015)
- Ischemic Optic Neuropathy Decompression Trial Research Group, "Ischemic optic neuropathy decompression trial : twenty-four-month update", Arch Ophthalmol, 118, pp.793~798 (2000)
- Lantos K, "Efficacy of treatments in nonarteritic ischemic optic neuropathy : a systematic review and meta-analysis", Int J Environ Res Public Health, 19, pp.2718~ (2022)
- Levin LA, "Retinal ganglion cells and neuroprotection for glaucoma", Surv Ophthalmol, 48(Suppl 1), pp.S21~4 (2003)
- Berry S, "Nonarteritic anterior ischemic optic neuropathy: cause, effect, and management", Eye Brain, 9, pp.23~28 (2017)
- Hayreh SS, "Controversies on neuroprotection therapy in non-arteritic anterior ischaemic optic neuropathy", Br J Ophthalmol, 104, pp.153~156 (2020)
- Page MJ, "The PRISMA 2020 statement : an updated guideline for reporting systematic reviews", BMJ, 372, pp.n71~ (2021)
- Ouzzani M, "Rayyan : a web and mobile app for systematic reviews", Syst Rev, 5, pp.210~ (2016)
- Slater BJ, "Optic nerve inflammation and demyelination in a rodent model of nonarteritic anterior ischemic optic neuropathy", Invest Ophthalmol Vis Sci, 54, pp.7952~7961 (2013)
- Chang CH, "Neuroprotective effects of recombinant human granulocyte colony-stimulating factor(G-CSF)in a rat model of anterior ischemic optic neuropathy(rAION)", Exp Eye Res, 118, pp.109~116 (2014)
- Wen YT, "Early applications of granulocyte colony-stimulating factor(G-CSF)can stabilize the blood-optic-nerve barrier and ameliorate inflammation in a rat model of anterior ischemic optic neuropathy(rAION)", Dis Model Mech, 9, pp.1193~1202 (2016)
- Liu PK, "Neuroprotective effects of low-dose G-CSF plus meloxicam in a rat model of anterior ischemic optic neuropathy", Sci Rep, 10, pp.10351~ (2020)
- Georgiou T, "Neuroprotective effects of omega-3 polyunsaturated fatty acids in a rat model of anterior ischemic optic neuropathy", Invest Ophthalmol Vis Sci, 58, pp.1603~1611 (2017)
- Huang TL, "Algae oil treatment protects Retinal Ganglion Cells(RGCs)via ERK signaling pathway in experimental optic nerve ischemia", Mar Drugs, 18, pp.83~ (2020)
- Wen YT, "Inhibition of retinal ganglion cell loss by a novel ROCK inhibitor(E212)in ischemic optic nerve injury via antioxidative and anti-inflammatory actions", Invest Ophthalmol Vis Sci, 62, pp.21~ (2021)
- Yi Z, "Protective effects of intravitreal injection of the rho-kinase inhibitor Y-27632 in a rodent model of nonarteritic anterior ischemic optic neuropathy(rAION)", J Ophthalmol, 2020, pp.1485425~ (2020)
- Nguyen Ngo Le MA, "Therapeutic effects of puerarin against anterior ischemic optic neuropathy through antiapoptotic and anti-inflammatory actions", Invest Ophthalmol Vis Sci, 60, pp.3481~3491 (2019)
- Guo Y, "Topical trabodenoson is neuroprotective in a rodent model of anterior ischemic optic neuropathy(rNAION)", Transl Vis Sci Technol, 8, pp.47~ (2019)
- Wen YT, "The benefits and hazards of intravitreal Mesenchymal Stem Cell(MSC)based-therapies in the experimental ischemic optic neuropathy", Int J Mol Sci, 22, pp.2117~ (2021)
- Lin WN, "Haematococcus pluvialis-derived astaxanthin is a potential neuroprotective agent against optic nerve ischemia", Mar Drugs, 18, pp.85~ (2020)
- Mehrabian Z, "Oligodendrocyte death, neuroinflammation, and the effects of minocycline in a rodent model of nonarteritic anterior ischemic optic neuropathy (rNAION)", Mol Vis, 23, pp.963~976 (2017)
- Goldenberg-Cohen N, "Possible neuroprotective effect of brimonidine in a mouse model of ischaemic optic neuropathy", Clin Exp Ophthalmol, 37, pp.718~729 (2009)
- Allen RS, "Progesterone treatment in two rat models of ocular ischemia", Invest Ophthalmol Vis Sci, 56, pp.2880~2891 (2015)
- Chou YY, "The protective effects of n-butylidenephthalide on retinal ganglion cells during ischemic injury", Int J Mol Sci, 23, pp.2095~ (2022)
- Li L, "Efficacy of Vincamine treatment in a rat model of anterior ischemic optic neuropathy", Eur J Ophthalmol, 31, pp.3442~3449 (2021)
- Johnson MA, "Anti-NOGO antibody neuroprotection in a rat model of NAION", Transl Vis Sci Technol, 10, pp.12~ (2021)
- Touitou V, "Sustained neuroprotection from a single intravitreal injection of PGJ2 in a rodent model of anterior ischemic optic neuropathy", Invest Ophthalmol Vis Sci, 54, pp.7402~7409 (2013)
- Bernstein SL, "Estrogen is not neuroprotective in a rodent model of optic nerve stroke", Mol Vis, 13, pp.1920~1925 (2007)
- Avraham-Lubin BC, "Neuroprotective effect of hyperbaric oxygen therapy on anterior ischemic optic neuropathy", Front Neurol, 2, pp.23~ (2011)
- Lyttle DP, "Levodopa as a possible treatment of visual loss in nonarteritic anterior ischemic optic neuropathy", Graefes Arch Clin Exp Ophthalmol, 254, pp.757~764 (2016)
- Nikkhah H, "The effect of systemic erythropoietin and oral prednisolone on recent-onset non-arteritic anterior ischemic optic neuropathy : a randomized clinical trial", Graefes Arch Clin Exp Ophthalmol, 258, pp.2291~2297 (2020)
- Parisi V, "Neuroenhancement and neuroprotection by oral solution citicoline in non-arteritic ischemic optic neuropathy as a model of neurodegeneration : a randomized pilot study", PLoS One, 14, pp.e0220435~ (2019)
- Hooijmans CR, "SYRCLE’s risk of bias tool for animal studies", BMC Med Res Methodol, 14, pp.43~ (2014)
- McGuinness LA, "Risk-of-bias VISualization(robvis) : an R package and Shiny web app for visualizing risk-of-bias assessments", Res Synth Methods, 12, pp.55~61 (2021)
- Sterne JA, "RoB 2 : a revised tool for assessing risk of bias in randomized trials", BMJ, 366, pp.l4898~ (2019)
- "The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses" (2013)[URL]
- Barkana Y, "Neuroprotection in ophthalmology : a review", Brain Res Bull, 62, pp.447~453 (2004)
- Park CH, "Neuroprotective effect of citicoline against KA-induced neurotoxicity in the rat retina", Exp Eye Res, 81, pp.350~358 (2005)
- Rejdak R, "Citicoline treatment increases retinal dopamine content in rabbits", Ophthalmic Res, 34, pp.146~149 (2002)
- Peeler C, "Non-arteritic anterior ischemic optic neuropathy(NAION) : a review and update on animal models", Semin Ophthalmol, 31, pp.99~106 (2016)
- Huang TL, "Efficacy of intravitreal injections of triamcinolone acetonide in a rodent model of nonarteritic anterior ischemic optic neuropathy", Invest Ophthalmol Vis Sci, 57, pp.1878~1884 (2016)